Literature DB >> 7614469

Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.

B W Hughes1, A H Wells, Z Bebok, V K Gadi, R I Garver, W B Parker, E J Sorscher.   

Abstract

We used a gene transfer-based system to generate highly toxic purine bases in tumor cells transfected with the Escherichia coli purine nucleoside phosphorylase (PNP) gene. Because these toxic purines are membrane permeant, they mediate effective killing of neighboring cells that do not express E. coli PNP ("bystander" toxicity). In mixed cultures containing increasing percentages of cells with gene expression, 100% cancer cell growth arrest and total population killing was demonstrated when as few as 1-2% of cells expressed E. coli PNP. We used E. coli PNP to test bystander killing of human melanoma cells. A 529-bp region upstream of the human tyrosinase gene start site was shown to direct melanoma-specific expression in human cell lines. When this human tyrosinase regulatory region was used to control E. coli PNP expression, profound toxicity was observed in melanoma cells after treatment with the relatively nontoxic substrate 6-methylpurine-deoxyriboside, which is converted by E. coli PNP into the highly toxic purine base 6-methylpurine. Bystander toxicity was estimated as at least 100 cells killed for each cell expressing E. coli PNP, a level substantially higher than that of other tumor sensitization genes currently being used in clinical trails. These results suggest that the high bystander activity of the system could lead to significant antimelanoma responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Identification of the tautomeric form of formycin A in its complex with Escherichia coli purine nucleoside phosphorylase based on the effect of enzyme-ligand binding on fluorescence and phosphorescence.

Authors:  Jakub Włodarczyk; Gerasim Stoychev Galitonov; Borys Kierdaszuk
Journal:  Eur Biophys J       Date:  2003-12-04       Impact factor: 1.733

2.  Experimental studies on PNP suicide gene therapy of hepatoma.

Authors:  Xiaokun Cai; Junli Zhou; Jusheng Lin; Xuemei Sun; Xiulan Xue; Chao Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Preliminary crystallographic studies of purine nucleoside phosphorylase from the cariogenic pathogen Streptococcus mutans.

Authors:  Qiao Ming Hou; Xiang Liu; Erik Brostromer; Lan Fen Li; Xiao Dong Su
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-11-27

Review 4.  Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Authors:  Andressa Ardiani; Adam J Johnson; Hongmei Ruan; Marilyn Sanchez-Bonilla; Kinta Serve; Margaret E Black
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

5.  PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

Authors:  Eric J Sorscher; Jeong S Hong; William B Parker
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

6.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

7.  Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Authors:  Abdalla E A Hassan; Reham A I Abou-Elkhair; James M Riordan; Paula W Allan; William B Parker; Rashmi Khare; William R Waud; John A Montgomery; John A Secrist
Journal:  Eur J Med Chem       Date:  2011-11-04       Impact factor: 6.514

8.  The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.

Authors:  William B Parker; Paula W Allan; William R Waud; Jeong Hong; Melissa Gilbert-Ross; B R Achyut; Disha Joshi; Turang Behbahani; Regina Rab; Steven E Ealick; Eric J Sorscher
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-08       Impact factor: 3.333

9.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

10.  Purine nucleoside phosphorylase from Pseudoalteromonas sp. Bsi590: molecular cloning, gene expression and characterization of the recombinant protein.

Authors:  Xiaohui Li; Xinyin Jiang; Huirong Li; Daming Ren
Journal:  Extremophiles       Date:  2008-02-26       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.